Advances in antibody-drug conjugates in the treatment of advanced triple-negative breast cancer: a narrative review.

ABSTRACT:

Background and objective

Triple-negative breast cancer (TNBC) is more aggressive when compared with other breast cancer subtypes, and advanced TNBC (aTNBC) has always been a challenge for clinical treatment. In recent years, significant progress has been made in the research of antibody-drug conjugates (ADCs), especially targeting trophoblast cell-surface antigen 2 (TROP2), as an effective regimen to enhance the potential survival benefit and quality of life of relevant patients. The objective of this narrative review is to provide a comprehensive knowledge on latest progress of ADCs in the treatment of aTNBC. Furthermore, the clinical significance and future research directions for ADCs are also discussed.

Methods

As of December 2023, literature spanning the past decade was

SUBMITTER: Jiang K 

PROVIDER: S-EPMC11836745 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature